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Abstract
Background: The potential role of DSS in CVD prevention remains unclear as only a few studies report on patient outcomes
for cardiovascular disease.
Methods and Results: A systematic review and meta-analysis of randomised controlled trials and observational studies was
done using Medline, Embase, Cochrane Library, PubMed, Amed, CINAHL, Web of Science, Scopus databases; reference lists
of relevant studies to 30 July 2011; and email contact with experts. The primary outcome was prevention of cardiovascular
disorders (myocardial infarction, stroke, coronary heart disease, peripheral vascular disorders and heart failure) and
management of hypertension owing to decision support systems, clinical decision supports systems, computerized decision
support systems, clinical decision making tools and medical decision making (interventions). From 4116 references ten
studies met our inclusion criteria (including 16,312 participants). Five papers reported outcomes on blood pressure
management, one paper on heart failure, two papers each on stroke, and coronary heart disease. The pooled estimate for
CDSS versus control group differences in SBP (mm of Hg) was - 0.99 (95% CI 23.02 to 1.04 mm of Hg; I2 = 0; p = 0.851).
Conclusions: DSS show an insignificant benefit in the management and control of hypertension (insignificant reduction of
SBP). The paucity of well-designed studies on patient related outcomes is a major hindrance that restricts interpretation for
evaluating the role of DSS in secondary prevention. Future studies on DSS should (1) evaluate both physician performance
and patient outcome measures (2) integrate into the routine clinical workflow with a provision for decision support at the
point of care.
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Introduction
Although numerous guidelines exist for prevention of CVD, risk
factor control remains sub-optimal in high-risk patients and in
those with established CVD [1]. Physician adherence to guidelines
for prevention of CVD in general has been less than optimal [2],
[3]. Moreover, published literature has demonstrated a ‘discrep-
ancy between intentions and practise’ in the treatment of
hypertension and have highlighted the physicians’ difficulty in
following the complex clinical guidelines [4].
Decision support systems defined as ‘any intervention that
provides clinicians with clinical knowledge and patient specific
information to augment patient care decisions’ [5] have been
introduced in the developed world as tools for implementing
guidelines. Numerous systematic reviews have shown that
Computerised Decision Support Systems (CDSS) when used as
reminders improve preventive care, enhance clinical performance,
influence clinical decision making [6,7,8,9,10,11] and significantly
improve the decision quality [12,13].
Although DSS could be efficient and low cost tools for primary
care in the prevention of cardiovascular disease, only a few studies
report on patient outcomes for cardiovascular disease and the
potential role of DSS for the CVD prevention remains unclear [8].
Hence, we aimed to systematically search for all the available
studies that report the effect of DSS on prevention of cardiovas-
cular disease. Furthermore, we aimed to evaluate whether this
effect would differ by type of cardiovascular disorder and in
primary or secondary prevention.
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Methods
We conducted a systematic review and meta-analysis of studies
that evaluated the role of DSS in prevention of CVD among
adults.
Search Strategy and Eligibility Criteria
Between November 2010 and 30 Jul 2011 (last date searched)
we comprehensively searched the following databases: Medline
(1950 to present), EMBASE (1980 to present), the Cochrane
Library (1960 to present), Scopus (1996 to present), Scielo (1997 to
present), Web of knowledge (1970 to present), AMED (1985 to
present) and CINHAL (1981 to present).
We used combinations of text words and thesaurus terms that
included secondary prevention’’[All Fields] AND (Humans[Mesh]
AND adult[MeSH]))) OR (primary prevention AND (Humans
[Mesh] AND adult[MeSH]))) OR (‘‘secondary prevention’’[MeSH
Major Topic] AND (Humans[Mesh] AND adult[MeSH]))) OR
(‘‘primary prevention’’[MeSH Major Topic] AND (Humans
[Mesh] AND adult[MeSH]))) OR (‘‘prevention’’[All Fields]
AND (Humans[Mesh] AND adult[MeSH])) AND (Humans
[Mesh] AND adult[MeSH]))) AND (((((((((((cardiovascular diseases))
OR (cardiovascular disorders)) OR (‘‘cardiovascular diseases’’
[MeSH Major Topic]))) OR ((((peripheral vascular disorders)) OR
(peripheral vascular diseases)) OR (‘‘peripheral vascular disea-
ses’’[MeSH Terms]))) OR (((‘‘heart failure’’[All Fields])) OR
(‘‘heart failure’’[MeSH Major Topic]))) OR ((((((coronary heart
diseases)) OR (coronary arterial diseases)) OR (‘‘coronary arterial
disease’’[All Fields])) OR (‘‘coronary heart disease’’[All Fields]))
OR (‘‘coronary occlusion’’[MeSH Major Topic]))) OR ((((((((brain
vascular event)) OR (cerebral stroke)) OR (cerebrovascular event))
OR (cerebrovascular accident)) OR (‘‘cerebrovascular trauma’’
[MeSH Major Topic])) OR (‘‘cerebrovascular disorders’’[MeSH
Major Topic])) OR (‘‘stroke’’[MeSH Major Topic]))) OR
(((((‘‘heart attack’’[All Fields])) OR (ischemic heart disease)) OR
(myocardial infarction)) OR (‘‘myocardial ischemia’’[MeSH Major
Topic]))) OR (((((diastloc blood pressure)) OR (systolic blood
pressure)) OR (blood pressure)) OR (‘‘hypertension’’[All Fields]))
AND (Humans[Mesh] AND adult[MeSH]))) AND ((((((((((‘‘clinical
decision support systems’’[All Fields] OR ‘‘clinical decision
support tool’’[All Fields] OR ‘‘clinical decision support tools’’[All
Fields])) OR (‘‘computerized decision support systems’’[All Fields]
OR ‘‘computerized decision support tool’’[All Fields] OR
‘‘computerized decision support tools’’[All Fields])) OR (clinical
decision making tools)) OR (computeri* AND decision support
systems)) OR (‘‘clinical decision support systems’’[All Fields])) OR
(‘‘decision support systems’’[All Fields])) OR (‘‘decision support
systems, clinical’’[MeSH Major Topic]))) OR (medical decision
making)).
Studies were included if they were:
1. Cross sectional, case control, cohort and randomized con-
trolled trials (RCTs).
2. Studies conducted among adult populations ($18 years old).
3. Studies on prevention of cardiovascular disorders (myocardial
infarction, stroke, coronary heart disease, peripheral vascular
disorders and heart failure) and management of hypertension
due to the types of interventions (defined in point number 4
below)
4. Studies on interventions including: decision support systems,
clinical decision supports systems, computerized decision
support systems, clinical decision making tools and medical
decision making
Articles were excluded if they were:
5. Letters, abstracts, conference proceedings, reviews and meta-
analysis
6. Not conducted in humans
Two independent reviewers working in pairs (RA and OHF, AS
and JS, LJ and RC) screened the titles and abstracts of the initially
identified studies to determine whether they would satisfy the
selection criteria. Any disagreements about selection were resolved
through consensus or consultation with a third author. Full text
articles were retrieved for the selected titles. Reference lists of the
retrieved articles were searched for additional publications. We
also contacted the authors of the retrieved papers directly for any
additional and unpublished studies. The retrieved studies were
assessed again by two independent authors (RA and OhF) to
ensure that they satisfied the inclusion criteria.
Data Extraction
A data collection form was designed prior to the implementa-
tion of the search strategy. This form was used by two independent
reviewers to extract the relevant information from the selected
studies (RA and OhF). The data collection form included
questions on qualitative aspects of the studies (e.g. date of
publication, design, geographic origin and setting, funding source,
selection criteria, patient samplings and location of research
group), participant characteristics (e.g. number of population
included in the analysis, age range, mean age, gender, ethnicity,
recruitment procedures, residential region, socio economic status,
comorbidities and drug treatment) characteristics of the exposure/
intervention evaluated (e.g. type, method used to measure) and
information on the reported outcomes (e.g. measure of disease
association, type of outcome, outcome assessment method, type of
statistical analysis, adjustment variables).
Statistical Analysis
A two sample t test yielded the mean difference (SE) in SBP
between both the intervention (DSS) and the control groups. A
fixed effects meta-analysis model was used to pool the mean
difference in SBP from all the five studies. The ‘‘I squared
statistic’’, which quantifies the percentage of variation attributable
to heterogeneity, was reported as a measure of consistency across
the studies. The mean SBP difference and the 95% CIs have been
reported in the pooled analysis.
Quality Evaluation
The quality of the studies included was evaluated using a scare
of maximum of 10 points (for the highest quality) 10 based on the
following aspects of the study: (1) Allocation to study groups (random,
2; quasi-random, 1; selected concurrent controls, 0); (2) Data
analysis and presentation of results (appropriate statistical analysis and
clear presentation of results, 2; Inappropriate statistical analysis or
unclear presentation of results, 1; inappropriate statistical analysis
and unclear presentation of results, 0); (3) Presence of baseline
differences between the groups that were potentially linked to study outcomes (no
baseline differences present or appropriate statistical adjustments
made for differences, 2; baseline differences present and no
statistical adjustments made, 1; baseline characteristics not
reported, 0); (4) Objectivity of the outcome (objective outcomes or
subjective outcomes with blinded assessment, 2; subjective
outcomes with no blinding but clearly defined assessment criteria,
1; subjective outcomes with no blinding and poorly defined, 0); (5)
Completeness of follow-up for the appropriate unit of analysis (90%, 2;from
80% to 90%, 1; ,80% or not described, 0).
DSS in Prevention of CVDs
PLOS ONE | www.plosone.org 2 October 2012 | Volume 7 | Issue 10 | e47064
Results
Study Selection
Overall 6076 references were initially identified in our study:
5995 from electronic databases and 81 from bibliographies and
experts (Figure 1). Full-text assessment of the 59 potentially
relevant articles resulted in 10 eligible studies that were included in
our analyses.
Characteristics of Studies Included
All the papers were published after the year 2000 and came
from high income and developed countries (table 1). Five studies
were conducted in the USA [14,15,16,17,18], two in UK [19,20],
one in Israel [21], one in Australia [22], and one in Canada [23].
Five papers reported outcomes on blood pressure management
[14,15,16,19,23], one on heart failure [22], two on Transient
Ischemic Attack (TIA) or stroke [17,20] and two on coronary heart
disease [18,21] (table 1). Seven papers were randomized trials
and the remaining three [17,18,22], were cohort studies. Eight of
the papers had a computerised decision support system (CDSS),
one had a telephone linked IT supported program [23] and the
remaining one [22] had written guideline reminders to physicians
coupled with education to the pharmacists. All the 10 papers had
the physicians as the DSS users. In addition, three papers had
support systems for the nurses [21,22,23] and two had interven-
tions which also involved the pharmacists [22,23]. Three were
conducted in inpatient settings [17,20,22]. Nine papers clearly
mentioned the source for the clinical knowledge in the decision
support systems (except Rinfret, 2009 [23]). Five papers reported
on primary prevention [14,15,16,19,23] and the other five papers
reported on secondary prevention. Two papers18, 19 scored poorly
on the quality ratings (five on a scale of ten). The remaining eight
papers were of a good quality (Table 1).
Effect of DSS on Prevention of CVD
The heterogeneity of the study outcomes precluded the pooling
of diverse outcomes that were reported. Two papers reported the
effect of computer based decision support for selecting the anti-
thrombotic therapy with either TIA/stroke as the primary end
point [17,20]. The selected paper on heart failure23 which
matched our search strategy reported no difference for the
composite outcome of death or readmission among the interven-
Figure 1. Flow diagram for the selection of studies evaluating the role of DSS in prevention of CVD.
doi:10.1371/journal.pone.0047064.g001
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Table 1. Intervention, outcomes and effect sizes for the selected studies.
Author, year of
publication
Sample size; mean age in
years (range or SD);
n (%) of females
Outcome;
type of
prevention
Type of
intervention Effect size
Quality
rating
Mudge et al [22],
(2010)
416; 75 yrs (24–100) and 78 yrs
(32–102); 103 (52) and 118
(54) females in the baseline
and intervention
cohorts respectively
Heart failure;
secondary
prevention
Decision support
tools, reminders,
education and
academic detailing,
and performance
feedback
There was a trend to increased readmissions
attributed to heart failure: 47 (21.5%) of
intervention patients
compared to
33 (16.7%)
in the baseline group
(OR = 1.30; 95% CI: 0.87–1.93).
8
Hayden B. Bosworth
et al [14], 2009
588; 63 yrs (11); 12 (2) females Blood pressure;
primary
prevention
Computerised
clinical decision
support system
Estimated mean systolic BP (SE) baseline, 24
Months (SE), baseline to 24 months difference (SE)
and
p value: (a) Reminder control:141.6 (1.4),
136.8
(1.6), 24.9 (1.9), .01 (b) Provider decision
support
intervention: 139.1(1.4),136.9 (1.6), 22.1 (1.9),
.27
(c) Patient behavioral intervention: 138.8
(1.4),
136.3(1.6), 22.5(2.0), .20 (d) Combined:
139.2 (1.4), 136.8 (1.7), 22.3 (2.1), .26
9
Ste´phane Rinfret et al
[23], 2009
223; 55 yrs (44–66) and 57 yrs
(44–70); 51 (45.9) and 51
(45.5) females in intervention
and control
groups respectively
Blood pressure;
primary
prevention
IT supported
management
program
Change in the mean 24-hour ambulatory BP:
consistently greater in intervention subjects for
both systolic (11.9 versus 7.1 mm Hg; p 0.001) and
diastolic BP (6.6 versus 4.5 mm Hg; p 0.007).
9
Harel Gilutz et al [21],
2009
7448 [Intervention (n = 3695)
Control (n = 3753)]; 65.3 yrs (9.8)
and
65.9 yrs (10.2); 1375 (37.21)
and 1409 (37.54) females
in intervention and
control groups respectively
Coronary artery
disease;
secondary
prevention
Computer-based
clinical decision
support system
A modest yet significant decrease of event-free
survival in the intervention arm, 57.1% vs. 59.2%
(P,0.03).
8
LeRoi S Hicks et al
[16], 2008
2027; median age 61, 64, 61,
62 yrs; 681(65), 521 (66), 83(69)
and 54 (74) females for the
Usual Care (UC), Computerised
decision support (CDS), nurse
practitioners (NP) in UC
and NP in CDS respectively
Blood pressure;
primary
prevention
Computerized
decision support
(1) Adjusted odds of BP control 20.96 (0.78–1.19)
for computerised support versus usual care
(2) Blood pressure controlled in n (%):Usual Care
527 (45%); Computerized
Support 410 (48%)
9
Michael D. Brown
et al [17], 2007
75; 67.1 yrs (19–100); 37 (49.3)
females
Transient
Ischemic Attack
(TIA)/stroke;
secondary
prevention
Computer-based
clinical support
(1) The 90-day risk of
recurrent TIA was seven out of 75 (9.3%); 95%
CI: 4.6% to 18.0%); (2) Recurrent
TIA - proportion (n): 0.093 (7)
(95% CI 20.05, 0.18)
5
Christianne L. Roumie
et al [15], 2006
1341; 65.1 yrs (11.9), 65.5 yrs(12.0)
and 64.6 yrs (12.6); 11(3.4), 15 (2.7)
and 19 (4) females for Provider
Education only, Provider Education
and Alert, Provider Education Alert
and Patient Education respectively
Blood pressure;
primary
prevention
Provider education
and alerts
Mean systolic blood pressure (SD), mm Hg: 157.3
(11.9), 158.0 (12.4) and 156.3 (11.4) in the ‘Provider
Education only’, ‘Provider Education and Alert’ and
‘Provider Education Alert, and Patient Education’
groups respectively
8
Prescription in
Ischaemic Stroke
Management (PRISM)
Group [20], 2003
1952; median - 73 yrs (64–80) and
73 yrs (62–80); 247 (53) and 126
(58) females for control and
intervention groups respectively
in phase 2
Stroke; secondary
prevention
Computerised
decision support
system
relative risk reduction (RRR) in percentage units for
ischaemic and haemorrhagic vascular events was 2.7
(20.3 to 5.7)
8
Richard I. Levin et al
[18], 2002
1628; - (35–85) yrs; 847 (52)
females
Acute Myocardial
Infarction;
secondary
prevention
Computer-based
clinical decision
support system
(ohms|cadH)
Acute myocardial infarctions were reduced by 30%
RR- 0.70 [95% CI: 0.59–0.81]
5
Alan A Montgomery
et al [19], 2000
614; 71 yrs (6), 70 yrs (6), 71 yrs
(5); 123 (54), 130 (57) and 77 (4)
females for the Computer support
plus chart, Chart only and Usual
care groups respectively
Blood pressure;
primary
prevention
Computer based
clinical decision
support system
The chart only group had significantly lower
systolic blood pressure compared with the usual
care
group (difference in means 24.6 mm Hg
(95%CI: 8.4 to 20.8)
9
Explanatory footnote: SD – Standard deviation; UC – Usual Care; CDS – Computerised decision support system; NP - nurse practitioners; Ohms|Cad – registered name
of the decision support system.
doi:10.1371/journal.pone.0047064.t001
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tion and control groups. Two papers [18,21] in which computer
based clinical decision support system was used showed significant
reduction in acute myocardial infarction and cardiovascular
related rehospitalizations.
Effect of DSS on Prevention of TIA/Stroke
PRISM, 2003 [20] was a cluster-randomized, controlled trial of
computer-based decision support for selecting long-term anti-
thrombotic therapy after acute ischaemic stroke. The median IQR
% relative risk reduction (RRR) in ischaemic and haemorrhagic
vascular events was 16.3 (13.1–23.8) and 16.7 (13.5–22.9) for
control and intervention groups respectively. In a fairly large
sample sized (n= 1952) prospective computer-based clinical
support study done by Brown [17], 2007, the mean RRR attained
by prescription when CDSS information was provided increased
by 2.7 percentage units (95% CI 20.3 to 5.7), which was not
significant. CDSS did not result in statistically significant results for
the odds ratio for the optimal therapy being prescribed
(OR=1.32; 95% CI: 0.83–1.80).
Effect of DSS on Prevention of Heart Failure
Only one paper on heart failure [22] met our selection criterion.
The multi-pronged intervention (decision support tools, reminders,
education and academic detailing, and regular performance
feedback) improved patient care processes at the cost of higher
readmission rates. There was a trend to increased readmissions
attributed to heart failure: 47 (21.5%) of intervention patients
compared to 33 (16.7%) in the baseline group (OR=1.30; 95%
CI: 0.87–1.93).
Effect of DSS on Prevention of Coronary Artery Disease
In a large sample sized (n= 7448) cluster randomized trial from
Israel22, an assessment of all cardiovascular related rehospitaliza-
tions (major and non-major cardiac effects) and all-cause mortality
during the first year revealed a significant decrease of event-free
survival in the intervention arm, 57.1% vs. 59.2% (P,0.03) at the
end of 6 months of follow up. Levin et al [18], in a prospective
cohort (n = 1628) done in USA, reported that their developed DSS
(ohms|Cad) which utilised patient- specific guidelines for coronary
prevention and elimination of ischemia as the knowledge base,
resulted in 30% reduction in acute myocardial infarctions relative
risk (RR), 0.70; 95% confidence interval (CI),0.59–0.81].
Effect of DSS on Management of Hypertension
Four [14,15,16,19] papers (which reported the effects of DSS on
SBP) had reported the mean (SE) differences in SBP between
baseline and end of study visit for both the intervention and
control groups. The SDs were calculated as square root of the
sample size in the control or intervention group times the SE. For
the study which reported the p values [16] for the differences
between the baseline and the repeat SBP, difference between
baseline and repeat measure (for that group) was divided by the Z
value (for that p value) to yield the SE. All of these were cluster
randomized trials.
Four of the five papers on hypertension management utilised a
computerised decision support system (CDSS). Figure 2(a) shows
the pooled estimate for CDSS versus control group differences in
SBP (mm of Hg) was - 0.99 (95% CI: 23.02 to 1.04 mm of Hg;
I2 = 0; p= 0.851). On inclusion of the paper which reported using
an Information technology assisted management program on BP
control in primary care [23], the pooled estimate for the SBP
difference among the intervention and control groups was
22.32 mm of Hg (95% CI: 23.96 to 20.69 mm of Hg). The I
squared (variation in the estimate attributable to heterogeneity)
was 27.9% (p= 0.236). Only two studies reported the DBP
measure for intervention and control groups [19,23]. The pooled
estimate for DBP difference among the intervention and control
group was 20.42 mm of Hg (95% CI: 22.30 to 1.47 mm of Hg)
which was not significant.
To substantiate the findings of the pooled estimate a power
analysis for the meta analysis on selected studies reporting effect of
CDSS on SBP was done due to the small number of the studies to
be included in the analysis. From the four papers reporting the
mean and standard deviations of both the intervention and control
group SBP (table 2) owing to the CDSS intervention, a pooled
standard deviation (SDp), total sample size and variance was
calculated. The overall mean effect size was calculated as a
weighted mean with samples weighted by their variance, vi
(related to their pooled sample sizes). Weights, wi, were calculated
from the inverse of vi. The SDp was calculated based on the
weightage given for each study.
Applying the formula n = [2 s2 (Za/2+ Zb )‘2/d] – formula 1,
where d denotes the expected mean difference (or difference worth
detecting), n the sample size and s the standard deviation of the
variable (pooled SD), the calculated Zb using the above formula
was 83.5 (when Za/2 was kept at 1.96). Hence, the power of the
meta analysed pooled SBP estimate was 83.5% (b=0.83).
Publication Bias
There was no evidence of significant publication bias after
assessing the funnel plot (Figure 2b) for the studies that reported
effects of DSS on management and control of BP.
Discussion
CDSS did not result in significant reduction of SBP and played
an insignificant role in the management and control of Blood
Pressure. Although individual studies having DSS as intervention
reported a decrease in the SBP measures, the pooled estimate for
CDSS did not result in significant reduction in SBP (estimate of -
0.99 mm of Hg; 95% CI: 23.02 to 1.04 mm of Hg). However,
when DSS was pooled with information technology assisted
management program, it showed a significant pooled estimate for
intervention versus control group differences in SBP (estimate of
22.32 mm of Hg; 95% CI: 23.96 to 20.69 mm of Hg). DSS
moderately enhanced secondary prevention measures and slightly
reduced the number of cardiovascular rehospitalizations in
patients suffering from heart failure in a short time. DSS induced
significant reduction in acute myocardial infarction in patients
suffering from coronary artery disease. In stroke/TIA, patient
related outcomes showed improvement on using the DSS or
computer based clinical support.
Comparison with the Literature
Previous systematic reviews have shown that DSS when used as
reminders improve preventive care, enhance clinical performance,
influence clinical decision making [6,7,8,9,10,11] and significantly
improve the decision quality [12,13]. These reviews focused on
physician performance and acceptability of the system among the
health care providers. This review was attempted to study the role
of DSS in primary and secondary prevention of CVDs since (1)
only a few studies report on patient outcomes for cardiovascular
disease and (2) the potential role of DSS in CVD prevention
remains unclear.
DSS in Prevention of CVDs
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Lack of Focus on Preventive DSS
Traditionally, DSS interventions have focused on patient
assessment and disease management at tertiary or secondary
levels of care. Preventive care was left out in the bargain. In a
seminal review paper on DSS, Kawamato listed the salient
features that are associated with an improved physician perfor-
mance and patient related outcomes. Integration of the DSS into
the routine clinical workflow, maintenance of electronic templates,
Figure 2. Meta analysed pooled estimate and funnel plot. 2(a): Pooled estimate for the difference in SBP (mm of Hg) between the CDSS versus
control groups. 2 (b): Funnel plot to assess publication bias.
doi:10.1371/journal.pone.0047064.g002
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provision of decision support at the location of care and provision
of recommendations for care (and not just assessments)7 are
important features for a tailor made DSS.
Strengths and Limitations of the Review
The pooled estimate for CDSS versus control group differences
in SBP derived in this paper is a fair result as all the studies that
reported the effect of CDSS on management and control of BP
were cluster randomized trials, wherein the clinical knowledge
base was based on standardized guidelines for management of BP.
Further, the power of the meta analysed pooled SBP estimate was
estimated as 83.5% (b=0.83), which supports the validity of the
pooled estimate for SBP. Although, the clinical knowledge base for
the CDSS was different in all the studies that reported outcomes
on BP control, they were tailor made for that country or condition
(ATHENA hypertension guidelines decision support system [14];
Israeli guidelines for the management of dyslipidemia [21]; JNC
VI and VII [16], AHA/ACC 2001 guidelines for cardiovascular
disease prevention; JNC VII [15]; and New Zealand guidelines for
management of hypertension [19]).
An exhaustive search of all available databases and reporting of
the PRISMA checklist give our review an objective framework,
upon which the conclusions have been drawn. However,
integration into workflow, attitude of providers, interface design,
hardware (all matter at least as much as and probably more than
the content and intent of the instrument - DSS) have not been
captured in our review as our focus was on ‘the effect of DSS on
patient related outcomes’. Potential confounding may arise as the
review had excluded studies that did not report outcomes (studies
that reported benefit of DSS on medicine prescription rate,
physician adherence and performance have not been included).
The heterogeneity in the included papers i.e, veteran population
not representative of the general population, absence of clear
delineation of effects of behavioral interventions and CDSS
intervention in the management of BP [14,23]; reliance on
medical charts to measure quality of care and blood pressure
control [16]; provision of only risk stratification in CDSS with no
inputs on drug dosages and treatment recommendations [19];
patient loss to follow up of more than 25% [15] limit study’s
findings on the effect of CDSS in the management of BP. Out of
the 4 cluster randomized trials that reported the effects of CDSS
on control of BP, the sample size calculations were not adjusted for
intra cluster correlation in two papers [15,16] which limits the
power needed for sample size estimations.
The paucity of data available is a major hindrance that restricts
interpretation for evaluating the role of DSS in secondary
prevention. Absence of holistic management of all the risk factors
and the change in the incidence of CAD owing to the time gap
between the baselines and intervention years [18], and a very short
follow up of 6 months [21] limit the findings in the role of DSS in
preventing CAD. Absence of pre and post intervention measures,
convenient sampling [17] and effect of the already existing local
prescription guidelines (other than the CDSS) on prescribing
practices [20] may limit findings on the role of DSS in prevention
of stroke/TIA.
Conclusions
DSS show an insignificant benefit in the management and
control of hypertension (insignificant reduction of SBP). The
paucity of well-designed studies on patient related outcomes is a
major hindrance that restricts interpretation for evaluating the role
of DSS in secondary prevention. Future studies on DSS should (1)
evaluate both physician performance and patient outcome
measures (2) integrate into the routine clinical workflow with a
provision for decision support at the point of care. The coming
decade will see most countries (including developing) implement-
ing information technology for preventive health care provision
and for an uniform standardization of the quality of health care
given. Hence, there exists an urgent unmet need for low cost
preventive DSS tools to be developed, pilot tested, implemented
and evaluated to assess the role of DSS tool in preventing the
rising burden of CVD.
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Table 2. Power analysis for the meta analysis on selected studies reporting effect of CDSS on SBP.
Study ID n1
Mean diff
SBP 1 SD 1 n2
Mean diff
SBP2 SD2 Weight (wi) weight * n b
1 Alan A Montgomery
et al
130 0.25 1.7 202 20.04 1.4 21.96 7290.72 0.83
2 Hayden B. Bosworth
et al
143 24.9 1.9 151 22.1 1.9 14.93 4389.42 0.79
3 Christianne L. Roumie
et al
324 212 21 547 211 21 49.63 43227.73 .0.99
4 LeRoi S Hicks et al 527 1 2.82 410 2 2.82 13.49 12640.13 0.88
Explanatory notes: Study ID indicates the primary authors of the study, n1 is the sample size in control group and n2 is the sample size in the intervention group, mean
diff SBP1 and mean diff SBP2 are the respective mean differences in systolic blood pressures before and after the study periods, SD1 and SD2 are the respective
standard deviations of both the groups, weightage is the estimated weight given to the study in the pooled analysis and b is the power of the individual studies
calculated from the formula 1 mentioned in the text.
doi:10.1371/journal.pone.0047064.t002
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